– SWITZERLAND, Lausanne – Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announced the appointment of Abbas Hussain as new Chair to its Board of Directors.
“Abbas has fantastic experience and a proven track record in the pharma industry which will be invaluable as we take Asceneuron into its next stage of growth and accelerate development of these potentially transformative therapies,” said Vice Chair of the Board of Directors, Henrijette Richter.
About Abbas Hussain
Abbas Hussain has over 35 years of experience in the healthcare industry, building and growing businesses across the globe. He has a strong track record across the pharmaceutical value chain in both mature and emerging markets. Abbas has held various senior leadership positions at world-leading pharma companies including GlaxoSmithKline, where he was President of Global Pharmaceuticals with responsibilities for operations in Europe, US, Asia, and emerging markets, and Eli Lilly, where he was President of Europe. He was CEO of Vifor Pharma which was acquired by CSL Limited in 2022 for $11.7 billion in one of the largest healthcare deals of the year.
Abbas Hussain said: “There have been tremendous advances in the treatment of neurodegenerative disorders which impact millions of people globally every year. Asceneuron is developing potentially transformative therapies that have the potential to slow disease progression and I am delighted to be joining the team at a pivotal time of transition and growth.”
Abbas currently holds various Non-Executive Director and Advisor roles at Alfasigma SpA, 4Bio Capital, C-Bridge Capital, and GLG Institute. He previously held various Non-Executive Director roles at Cochlear Limited, CSL Limited, Teva Pharmaceutical, Immunocore, and advisory roles with Hikma Plc, Cell Research Corp, Abingworth and Indegene Inc. In addition, Abbas also provides expert advisory services to private equity and venture capital firms focused on the healthcare sector.
He holds a Bachelor of Science in Medicinal and Pharmaceutical Chemistry from Loughborough Institute of Technology (UK) and is a graduate of the Stanford Executive Program at Stanford University (California, USA).
About Asceneuron
Asceneuron is a clinical-stage biotech company focused on the development of oral bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical needs. The company’s pipeline reflects its ambition and commitment to developing treatments for a wide range of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease, as well as orphan tauopathies. Asceneuron has two clinical-stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies: OGA inhibitor ASN90 (licensed to Ferrer Pharmaceuticals) for the treatment of progressive supranuclear palsy (PSP) and a potential best-in-class OGA inhibitor, ASN51 for Alzheimer’s disease.
SOURCE: https://www.asceneuron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
